>R&D
>R&D in Takeda
Takeda determines its R&D strategy based on the latest medical needs. By concentrating investment of management resources in the core therapeutic areas of Cardiovascular & Metabolic, Oncology, Central Nervous System, Immunology & Respiratory, General Medicine and Vaccine, Takeda strives to achieve leading innovation in medicine.
| Main R&D Facilities |
Takeda Pharmaceuticals International, Inc. (Deerfield, U.S.) Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. ( São Jerônimo, Brazil) Millennium Pharmaceuticals, Inc. (Cambridge, MA, U.S.) Takeda California, Inc. (San Diego, CA, U.S.) Envoy Therapeutics, Inc. (San Diego, CA, U.S.) Takeda Vaccines (Montana), Inc. (Bozeman, MT, U.S.) Takeda Global Research & Development Center, Inc. (Deerfield, IL. U.S.) Takeda Ventures, Inc. (Palo Alto, CA, U.S.) Takeda GmbH (Konstanz, Germany) Takeda Pharma A/S (Roskilde, Denmark) Takeda Cambridge Limited (Cambridge, U.K.) Takeda Global Research & Development Centre (Europe), Ltd. (London, U.K.) Takeda Global Research & Development Center (Asia) Pte. Ltd. (Singapore) Shonan Research Center (Fujisawa, Japan) |
|---|---|
| R&D Investment | ¥324.3 billion (FY2012) |
| Royalty Income | ¥45.2 billion (FY2012) |
| Core Therapeutic Areas | Cardiovascular & Metabolic Oncology Central Nervous System Immunology & Respiratory General Medicine Vaccine |
| R&D Pipeline | Takeda discloses ethical drugs under development that have reached phase I or higher status |